Dapoxetine CAS: 119356-77-3

 
· Dapoxetine
· Alias: Dapoxetine, d-Dapoxetine; DL-Dapoxetine
· CAS Registry Number: 129938-20-1
· Assay: 98% min.
· MF: C9H7ClN2O5
· MW: 341.88
· Related Substances: Pharmaceutical Grade
· Storage: Shading, confined preservation
· Character: White to Off-White Cyrstalline Solid

Application:
 
Dapoxetine is a white powder substance and water-soluble. Taken 1-3 hours before sexual activity, it is rapidly absorbed in the body. Its maximum plasma concentration (Cm) is reached 1-2 hours after oral administration.
 
Randomized, double blind, placebo-controlled trials have confirmed the efficacy of dapoxetine for the treatment of PE. Different dosage has different impacts on different type of PE. Dapoxetine 60 mg significantly improves the mean intravaginal ejaculation latency time (IELT) compared to that of dapoxetine 30 mg in men with lifelong PE, but there is no difference in men with acquired PE. Dapoxetine, given 1-3 hours before sexual episode, prolongs IELT, increases the sense of control and sexual satisfaction in men of 18 to 64 years of age with PE. Since PE is associated with personal distress, interrelationship difficulty, dapoxetine provides help for men with PE to overcome this condition. Because lack of specific approval treatment for PE in the US and some other countries, other SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, and citalopram have been used as off label drugs to treat PE.
Waldinger's meta analysis shows that the use of these conventional antidepressants increasing IELT from two to ninefold above base line in comparison of three to eightfold when dapoxetine is used. However, these SSRIs must be taken daily in order to achieve meaningful efficacy, and the long half-life increases the risk of the drug accumulation and as a consequence increased of adverse effects such as decreasing sexual libido and causing erectile dysfunction.